Low Dose Pasteur Bacillus Calmette-Guerin Regimen in Stage T1, Grade 3 Bladder Cancer Therapy
- 1 November 1996
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 156 (5) , 1602-1605
- https://doi.org/10.1016/s0022-5347(01)65458-2
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Improving the Efficacy of BCG Immunotherapy by Dose ReductionEuropean Urology, 1995
- Improving the Safety of BCG Immunotherapy by Dose ReductionEuropean Urology, 1995
- Dose-Response of Bacillus Calmette-Guerin in the Treatment of Superficial Bladder CancerJournal of Urology, 1992
- Bacillus Calmette-Guerin Therapy for Superficial Bladder Cancer: A 10-Year FollowupJournal of Urology, 1992
- A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette–Guérin for Transitional-Cell Carcinoma of the BladderNew England Journal of Medicine, 1991
- A Low Dose Bacillus Calmette-Guerin Regimen in Superficial Bladder Cancer Therapy: Is it Effective?Journal of Urology, 1991
- Bacillus Calmette-Guerin Versus Doxorubicin Versus Thiotepa: A Randomized Prospective Study in 202 Patients with Superficial Bladder CancerJournal of Urology, 1990
- Bladder Tumors Invading the Lamina propria (Stage A/Tl): Influence of Endovesical Bacillus Calmette-Guérin Therapy on Recurrence and ProgressionEuropean Urology, 1989
- Immunotherapy of Murine Transitional Cell CarcinomaJournal of Urology, 1982
- Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder TumorsJournal of Urology, 1976